Non Insulin Anti diabetes Drugs Market was valued at USD 37 Billion in 2022 and is projected to reach USD 65 Billion by 2030, growing at a CAGR of 7% from 2024 to 2030.
In 2018, the global market was valued at approximately USD 25 billion and exhibited a compound annual growth rate (CAGR) of around 5.7% through 2022. This growth trajectory was largely fueled by the increasing adoption of these medications due to their efficacy in managing blood sugar levels without the complexities associated with insulin. By 2022, the market reached an estimated USD 32 billion, with a growing number of diabetic patients choosing oral medications to manage their condition.
In the 2023 to 2033 outlook, the demand for non-insulin anti-diabetes drugs is expected to rise significantly, with projections indicating a potential CAGR of 7.5% during this period. This forecast reflects the ongoing advancement in drug development, better patient compliance, and expanding access to treatment in emerging markets. The market dynamics are influenced by several factors, including an increase in sedentary lifestyles, poor dietary habits, and the growing obesity epidemic.
Moreover, advancements in the pipeline, such as new combination therapies, have bolstered the demand for these medications. For instance, the potential approval of novel GLP-1 and SGLT2 combination therapies is expected to enhance market growth. Additionally, the incorporation of more convenient dosing regimens, such as once-weekly injections or oral tablets, is likely to drive further adoption.
While the market outlook remains positive, there are challenges ahead. Increasing regulatory scrutiny, pricing pressures, and the growing competition from biosimilars and generics pose potential risks to market growth. However, the increasing demand for effective, convenient, and cost-efficient treatments is expected to support the overall expansion of the non-insulin anti-diabetes drugs market.
Get an In-Depth Research Analysis of the Global Non Insulin Anti diabetes Drugs Market Size And Forecast [2025-2032]
The global market for non-insulin anti-diabetes drugs has seen substantial growth from 2018 to 2022, driven by increasing diabetes prevalence and the rising adoption of oral medications over insulin-based treatments. Non-insulin anti-diabetes drugs, which include classes such as DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors, gained significant market share during this period. The growing awareness of type 2 diabetes management, alongside advancements in drug formulations, has made these treatments a preferred choice for patients.
Â
Sanofi
Abbott
AstraZeneca
Eli Lilly
Roche
GlaxoSmithKline
Johnson & Johnson
Novartis
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Non Insulin Anti diabetes Drugs Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Non Insulin Anti diabetes Drugs Market
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Based on Types the Market is categorized into Below types that held the largest Non Insulin Anti diabetes Drugs market share In 2023.
Oral Drugs
Injectable Drugs
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Non Insulin Anti diabetes Drugs Market Research Analysis
1. Introduction of the Global Non Insulin Anti diabetes Drugs Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Non Insulin Anti diabetes Drugs Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Non Insulin Anti diabetes Drugs Market, By Type
6. Global Non Insulin Anti diabetes Drugs Market, By Application
7. Global Non Insulin Anti diabetes Drugs Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Non Insulin Anti diabetes Drugs Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/